State Street Corp Caladrius Biosciences, Inc. Transaction History

State Street Corp

  • $2.41 Trillion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022
BUY
$0.63 - $1.03 $3,969 - $6,489
6,300 Added 3.01%
215,261 $155,000
Q4 2021

Feb 14, 2022
SELL
$0.83 - $1.22 $7,138 - $10,492
-8,600 Reduced 3.95%
208,961 $176,000
Q3 2021

Nov 15, 2021
BUY
$1.15 - $1.57 $11,730 - $16,014
10,200 Added 4.92%
217,561 $265,000
Q2 2021

Aug 16, 2021
BUY
$1.4 - $1.9 $290,305 - $393,985
207,361 New
207,361 $334,000

About CALADRIUS BIOSCIENCES, INC.

CLBS Quotes by TradingView
  • Ticker CLBS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,583,200
  • Market Cap $25.8M
  • Description
  • Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...
More about CLBS
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email